New Delhi: Under its Network of Phase 1 Clinical Trials, the Indian Council of Medical Research (ICMR) has formalized Memoranda of Understanding (MoUs) with multiple entities to strengthen India’s clinical research ecosystem. The initiative is a key milestone in developing advanced, affordable, and accessible treatments for all citizens for a multitude of diseases.
The collaborations include:
Research with Aurigene Oncology Limited over a small molecule for multiple myeloma.
Partnering with Indian Immunologicals Limited for Zika vaccine development.
Coordinating with Mynvax Private Limited for seasonal Influenza virus vaccine trial.
Conducting a study with ImmunoACT on CAR-T cell therapy advancement for a new indication of chronic lymphocytic leukemia.
The project comprises four institutions across India—KEMH & GSMC, Mumbai; ACTREC, Navi Mumbai; SRM MCH&RC, Kattankulathur; and PGIMER, Chandigarh. They will be supported by a Central Coordinating Unit at ICMR Headquarters, New Delhi. Dr. Rajiv Bahl, Secretary, Department of Health Research & Director General, ICMR, while emphasizing the significance of the initiative, stated that the collaboration reflects ICMR’s commitment to advancing clinical research in India through strategic public-private partnerships. It will foster India’s capacity to develop new drugs, thereby reducing dependency on international resources, and ultimately driving the mission of affordable, high-quality healthcare for all.
